BioSpace News Archive

Humacyte, Inc. today announced financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate accomplishments.

In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to increase awareness for Lipoprotein(a) (Lp(a)). High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions.

89bio, Inc. today announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25.

Purple Biotech Ltd. today announced that the CEO, Gil Efron, has been hospitalized following an accident and will be on medical leave that is expected to last several months while he undergoes rehabilitation to recover from his injuries.

ASLAN Pharmaceuticals today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.

Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, announced a corporate update and reported its annual results for the year ended December 31, 2022.

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, reported that CEO Ryan Davies discussed the future of the cancer therapeutic industry with Dr. Looper, a life-long researcher in the chemistry field.

Oncorus, Inc. today reported fourth quarter and full year 2022 financial results and provided an update on its business.

atai reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights.

Midatech Pharma PLC is pleased to announce that at the general meeting of the Company held earlier today all resolutions put to the Company’s shareholders were duly passed.